AbbVie Eyes 2026 Growth as Diversified Drug Portfolio Takes Shape
At the beginning of 2026, AbbVie is making a fresh transition from its blockbuster drug Humira. This drug has been the corporate identity of AbbVie for over a decade. Numerous diseases and physical conditions were treated using Humira for the past decade, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. The transition from Humira marks … Read more



